These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26980467)

  • 1. [New medicines at an acceptable cost?].
    Bijl D
    Ned Tijdschr Geneeskd; 2015; 160():D170. PubMed ID: 26980467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
    Gronde TV; Uyl-de Groot CA; Pieters T
    PLoS One; 2017; 12(8):e0182613. PubMed ID: 28813502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underuse of innovative medicines in Germany: A justification for government intervention?
    Gandjour A
    Health Policy; 2018 Dec; 122(12):1283-1286. PubMed ID: 30389185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic conditions, financial burden and pharmaceutical pricing: insights from Australian consumers.
    Whitty JA; Sav A; Kelly F; King MA; McMillan SS; Kendall E; Wheeler AJ
    Aust Health Rev; 2014 Nov; 38(5):589-95. PubMed ID: 25099307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.
    Rigter H
    Pharmacoeconomics; 1994; 6 Suppl 1():15-21. PubMed ID: 10155581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is a new drug worth? An innovative model for performance-based pricing.
    Dranitsaris G; Dorward K; Owens RC; Schipper H
    Eur J Cancer Care (Engl); 2015 May; 24(3):313-20. PubMed ID: 25256668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Daniel K. Inouye College of Pharmacy Scripts: Prescription Drug Pricing.
    Sumida WK; Taniguchi R; Juarez DT
    Hawaii J Med Public Health; 2016 Jan; 75(1):25-30. PubMed ID: 26870605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expensive medicines: ensuring objective appraisal and equitable access.
    Hill SR; Bero L; McColl G; Roughead E
    Bull World Health Organ; 2015 Jan; 93(1):4. PubMed ID: 25558099
    [No Abstract]   [Full Text] [Related]  

  • 11. A proposal for value informed, affordable ("via") prices for innovative medicines.
    Annemans L
    J Med Econ; 2019 Nov; 22(11):1235-1239. PubMed ID: 31199174
    [No Abstract]   [Full Text] [Related]  

  • 12. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discounting of medicines in Australian community pharmacies.
    Thai LP; Vitry AI; Moss JR
    Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Availability and Pricing New Medicines in Ireland: Reflections and Reform.
    Gorecki PK
    Pharmacoeconomics; 2017 Oct; 35(10):981-987. PubMed ID: 28681277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of genetics in the Dutch health care system; a memorandum from the Dutch Minister of Health, Welfare and Sports to the Dutch Parliament].
    Leschot NJ
    Ned Tijdschr Geneeskd; 2001 Jun; 145(26):1233-5. PubMed ID: 11455687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value-Based Pricing and State Reform of Prescription Drug Costs.
    Hwang TJ; Kesselheim AS; Sarpatwari A
    JAMA; 2017 Aug; 318(7):609-610. PubMed ID: 28692713
    [No Abstract]   [Full Text] [Related]  

  • 17. Reducing Branded Prescription Drug Prices: A Review of Policy Options.
    Alexander GC; Ballreich J; Socal MP; Karmarkar T; Trujillo A; Greene J; Sharfstein J; Anderson G
    Pharmacotherapy; 2017 Nov; 37(11):1469-1478. PubMed ID: 28805961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use.
    Robinson JC; Howell S
    Health Aff (Millwood); 2014 Oct; 33(10):1745-50. PubMed ID: 25288418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical counseling: Between evidence-based medicine and profits.
    Egorova SN; Akhmetova T
    Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
    Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
    J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.